Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.





Servier Group Reports Financial Year 2020

18.01.2022
Paris (ots/PRNewswire) - - Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates)
- Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates)
- An accelerated oncology strategy with the acquisition of the Agios Pharmaceuticals' oncology business in April 2021
- Sustained activity in cardiometabolism and a strong increase in sales of Daflon® for venous diseases
- A strengthened and balanced R&D portfolio offering hope for patients
Servier, an independent global pharmaceutical group, published its results for the 2020/21 financial year, ending on September 30, 2021, and presented its research and development pipeline.
Olivier Laureau, President of Servier: "In 2020/21, the Servier Group continued to grow despite a difficult environment. We have significantly strengthened our position in oncology with the acquisition of the Agios Pharmaceuticals' oncology business. The oncology strategy that we initiated in 2017 is now bringing results with new medicines and future indications for patients with hard-to-treat cancers. Our position in cardiometabolism remains very significant and our growth in venous diseases has been important. The Group has also initiated a deep digital transformation to accelerate its development and performance. We also strengthened our presence in key markets, particularly in Japan and the United States, while consolidating our production, bioproduction and R&D activities in France. Servier thus confirms its choice to maintain strong research and production capabilities in France, even though 96% of the Group brand-name medicines are distributed outside France. This choice contributes to the French and European health independence."
About Servier
Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. More information: servier.com
PDF - https://mma.prnewswire.com/media/1728574/Servier_Press_Co... pdf
Logo - https://mma.prnewswire.com/media/1389607/Servier_Logo.jpg
presse@servier.com
Digital press kit: http://www.ots.at/pressemappe/DE57381/aom
BSN Podcasts
Der Podcast für junge Anleger jeden Alters

Wiener Börse Plausch S2/32: P&G-Booster für Marinomed, AT&S nie höher, SBO verdoppelt, European Lithium gefährlich und ein Spoiler


 

Aktien auf dem Radar:Strabag, Rosenbauer, EVN, Warimpex, FACC, Immofinanz, voestalpine, CA Immo, Bawag, Erste Group, Semperit, BTV AG, Josef Manner & Comp. AG, Polytec Group, SBO, UBM, Wiener Privatbank, Oberbank AG Stamm, Zumtobel, Verbund, S Immo, Cisco, Porsche Automobil Holding, Qiagen, Fresenius Medical Care, Allianz, Deutsche Boerse, Delivery Hero, Deutsche Post, Fresenius, Zalando.


Random Partner

Hypo Oberösterreich
Sicherheit, Nachhaltigkeit und Kundenorientierung sind im Bankgeschäft Grundvoraussetzungen für den geschäftlichen Erfolg. Die HYPO Oberösterreich ist sicherer Partner für mehr als 100.000 Kunden und Kundinnen. Die Bank steht zu 50,57 Prozent im Eigentum des Landes Oberösterreich. 48,59 Prozent der Aktien hält die HYPO Holding GmbH. An der HYPO Holding GmbH sind die Raiffeisenlandesbank Oberösterreich AG, die Oberösterreichische Versicherung AG sowie die Generali AG beteiligt.

>> Besuchen Sie 61 weitere Partner auf boerse-social.com/partner


Mehr aktuelle OTS-Meldungen HIER


Meistgelesen
>> mehr


PIR-Zeichnungsprodukte
AT0000A2QDR0
AT0000A2SUY6
AT0000A2X950

Börse Social Club Board
>> mehr
    Star der Stunde: SBO 4.43%, Rutsch der Stunde: Mayr-Melnhof -0.75%
    wikifolio-Trades Austro-Aktien 15-16: SBO(2), AT&S(1)
    Österreich-Depots: Schnelle Gewinnmitnahme beim Verbund (Depot Kommentar)
    Star der Stunde: SBO 1.44%, Rutsch der Stunde: Erste Group -1%
    wikifolio-Trades Austro-Aktien 14-15: Bawag(1), AT&S(1)
    Star der Stunde: Rosenbauer 1.16%, Rutsch der Stunde: SBO -2.81%
    wikifolio-Trades Austro-Aktien 13-14: S Immo(2), Pierer Mobility(1), Telekom Austria(1), CA Immo(1), Porr(1), AT&S(1)
    Nachlese: Bernd Spalt, Parkpickerl, Urlaub mit der Wiener Börse, wikifolio hat einen Duft
    Star der Stunde: Marinomed Biotech 3.08%, Rutsch der Stunde: SBO -1.23%